Press Release Oct 01 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding the receipt of an Establishment Inspection Report from the USFDA for its transdermal manufacturing facility in Ahmedabad. The inspection took place in July and the facility has been classified as Voluntary Action Indicated. This announcement serves as a disclosure in accordance with regulatory requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 28 2024
- Press Release Sep 27 2024
- Press Release Sep 13 2024
- Press Release Sep 10 2024
- Zydus receives final approval from USFDA for Scopolamine Transdermal System 1 mg/3 days
Later from Zydus Lifesciences
- Press Release Oct 02 2024
- Press Release Oct 10 2024
- Press Release Oct 14 2024
- Press Release Oct 17 2024
- Press Release Oct 23 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences